Modulation of drug-drug interactions of vadadustat
AssigneesAkebia Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation
InventorsAjit CHAVAN, Rishikesh SAWANT, Yoshimasa KOKADO, Takehiro NANJO, Shuji KINOSHITA, Naomi KONISHI
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.
Claims198
A method of reducing or minimizing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug comprises multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of reducing or minimizing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of preventing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug comprises multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of preventing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of controlling drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug comprises multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of controlling drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of increasing bioavailability of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of increasing bioavailability of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of maintaining bioavailability of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of maintaining bioavailability of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of minimizing a decrease in the absorption of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of minimizing a decrease in the absorption of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of preventing a decrease in the absorption of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of preventing a decrease in the absorption of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of controlling a decrease in the absorption of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of controlling a decrease in the absorption of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of controlling drug-multivalent cation chelate formation comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of controlling drug-iron chelate formation comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of minimizing or reducing drug-multivalent cation chelate formation comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of minimizing or reducing drug-iron chelate formation comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of preventing drug-multivalent cation chelate formation comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a composition comprising multivalent cations,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of preventing drug-iron chelate formation comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an iron-containing composition,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein (a) is given at least 1 hour or at least 2 hours before and/or after taking (b).
A method of treating renal anemia (anemia secondary to or associated with chronic kidney disease), comprising administering to a subject having renal anemia an effective amount of a compound which is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1) or pharmaceutically acceptable salt, solvate, or hydrate thereof,
- wherein the compound is for administering together with one or more of oral iron-containing composition selected from sodium ferrous citrate, ferric citrate, and sucroferric oxyhydroxide.
A method of treating renal anemia (anemia secondary to or associated with chronic kidney disease), comprising administering to a subject having renal anemia an effective amount of a compound which is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1) or pharmaceutically acceptable salt, solvate, or hydrate thereof,
- wherein the compound is for administering together with an oral calcium-containing composition that is calcium acetate or calcium carbonate.
A method of treating renal anemia (anemia secondary to or associated with chronic kidney disease), comprising administering to a subject having renal anemia an effective amount of a compound which is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1) or pharmaceutically acceptable salt, solvate, or hydrate thereof,
- wherein the compound is for administering together with an oral lanthanum-containing composition that is lanthanum carbonate.
A method of reducing or minimizing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a statin drug,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a statin drug,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a statin drug,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of maintaining bioavailability of a drug comprising administering to the subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a statin drug,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of minimizing an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a statin drug,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a statin drug,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a statin drug,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of reducing or minimizing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is an anti-inflammatory drug that is sulfasalazine,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is an anti-inflammatory drug that is sulfasalazine,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is an anti-inflammatory drug that is sulfasalazine,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of maintaining bioavailability of a drug, comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an anti-inflammatory drug that is sulfasalazine,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of minimizing an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an anti-inflammatory drug that is sulfasalazine,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an anti-inflammatory drug that is sulfasalazine,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of an anti-inflammatory drug that is sulfasalazine,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of reducing or minimizing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a diuretic that is furosemide,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a diuretic that is furosemide,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling drug-drug interaction between a first drug and a second drug comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a diuretic that is furosemide,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of maintaining bioavailability of a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a diuretic that is furosemide,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of minimizing an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a diuretic that is furosemide,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a diuretic that is furosemide,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling an increase in exposure to a drug comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a diuretic that is furosemide,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of treating renal anemia (anemia associated with or secondary to chronic kidney disease) in a subject with hepatic impairment, comprising administering to the subject an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof.
A method of reducing or minimizing drug-drug interaction between a first drug and a second drug or a metabolite thereof, comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a BCRP (breast cancer resistance protein) substrate,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing drug-drug interaction between a first drug and a second drug or a metabolite thereof, comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a BCRP (breast cancer resistance protein) substrate,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling drug-drug interaction between a first drug and a second drug or a metabolite thereof, comprising administering to a subject:
- (a) an effective amount of the first drug or a pharmaceutical composition comprising an effective amount of the first drug, wherein the first drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of the second drug, wherein the second drug is a BCRP (breast cancer resistance protein) substrate,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of maintaining bioavailability of a drug or a metabolite thereof, comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a BCRP (breast cancer resistance protein) substrate,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of minimizing an increase in exposure to a drug or a metabolite thereof, comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a BCRP (breast cancer resistance protein) substrate,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of preventing an increase in exposure to a drug or a metabolite thereof, comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a BCRP (breast cancer resistance protein) substrate,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of controlling an increase in exposure to a drug or a metabolite thereof, comprising administering to a subject:
- (a) an effective amount of a drug or a pharmaceutical composition comprising an effective amount of the drug, wherein the drug is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1);
- and
- (b) an effective amount of a drug that is a BCRP (breast cancer resistance protein) substrate,
- wherein the subject has renal anemia (anemia secondary to or associated with chronic kidney disease), and
- wherein the amount of (b) is adjusted compared to the amount when administered in the absence of (a) or in monotherapy.
A method of treating renal anemia (anemia associated with or secondary to chronic kidney disease) in a subject, comprising administering to the subject an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof,
- wherein the subject is receiving a drug that is a Breast Cancer Resistance Protein (BCRP) substrate.
A method of treating renal anemia (anemia associated with or secondary to chronic kidney disease) in a subject, comprising administering to the subject an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof,
- wherein the subject is receiving a diuretic that is furosemide.
A method of treating renal anemia (anemia associated with or secondary to chronic kidney disease) in a subject, comprising administering to the subject an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof,
- wherein the subject is receiving a statin drug.
A method of treating renal anemia (anemia associated with or secondary to chronic kidney disease) in a subject, comprising administering to the subject an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof,
- wherein the subject is receiving sulfasalazine.
Dependencies are inferred from the claim text.